Previous Close | 1.8600 |
Open | 1.9400 |
Bid | 2.1400 x 900 |
Ask | 2.3500 x 1100 |
Day's Range | 1.8400 - 1.9400 |
52 Week Range | 1.8200 - 11.8500 |
Volume | |
Avg. Volume | 39,743 |
Market Cap | 4.106M |
Beta (5Y Monthly) | 2.92 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -14.2900 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 76.25 |
Subscribe to Yahoo Finance Plus to view Fair Value for GOVX
ATLANTA, GA - (NewMediaWire) - March 12, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will pre...
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a significant milestone toward implementation of a validated chicken embryonic fibroblast (CEF) based production system for the company’s MVA-based vaccines, with the relea
GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Call Transcript March 1, 2024 GeoVax Labs, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome, everyone, to the GeoVax Fourth Quarter 2023 Corporate Update Call. My name is […]